Slovakia

Slovakia

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.81 (0.69 - 0.93) 2019 Modelled IHME
0.86 (0.75 - 0.96) 2018 Modelled IHME
0.88 (0.76 - 1) 2017 Modelled IHME
0.88 (0.76 - 0.99) 2016 Modelled IHME
0.87 (0.75 - 1) 2015 Modelled IHME
0.88 (0.75 - 1) 2014 Modelled IHME
0.89 (0.77 - 1.01) 2013 Modelled IHME
0.91 (0.78 - 1.03) 2012 Modelled IHME
0.93 (0.80 - 1.05) 2011 Modelled IHME
0.94 (0.81 - 1.07) 2010 Modelled IHME
0.96 (0.82 - 1.09) 2009 Modelled IHME
0.97 (0.84 - 1.11) 2008 Modelled IHME
0.99 (0.85 - 1.13) 2007 Modelled IHME
1.01 (0.86 - 1.15) 2006 Modelled IHME
1.02 (0.87 - 1.17) 2005 Modelled IHME
1.03 (0.89 - 1.18) 2004 Modelled IHME
1.05 (0.90 - 1.19) 2003 Modelled IHME
1.06 (0.91 - 1.21) 2002 Modelled IHME
1.08 (0.92 - 1.22) 2001 Modelled IHME
1.09 (0.92 - 1.24) 2000 Modelled IHME
1.11 (0.94 - 1.26) 1999 Modelled IHME
1.13 (0.96 - 1.27) 1998 Modelled IHME
1.15 (0.97 - 1.29) 1997 Modelled IHME
1.16 (0.98 - 1.31) 1996 Modelled IHME
1.16 (0.98 - 1.32) 1995 Modelled IHME
1.16 (0.98 - 1.32) 1994 Modelled IHME
1.16 (0.98 - 1.33) 1993 Modelled IHME
1.16 (0.99 - 1.33) 1992 Modelled IHME
1.16 (0.98 - 1.33) 1991 Modelled IHME
1.15 (0.97 - 1.33) 1990 Modelled IHME
1.1 (0.70 - 1.60) 2003 Survey/reported Nardone A et al, 2009
1.82 (1.48 - 2.25) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.04 (0.03 - 0.05) 2019 Modelled IHME
0.04 (0.03 - 0.05) 2018 Modelled IHME
0.04 (0.03 - 0.05) 2017 Modelled IHME
0.04 (0.03 - 0.05) 2016 Modelled IHME
0.04 (0.03 - 0.05) 2015 Modelled IHME
0.03 (0.02 - 0.04) 2014 Modelled IHME
0.03 (0.02 - 0.04) 2013 Modelled IHME
0.03 (0.02 - 0.04) 2012 Modelled IHME
0.03 (0.02 - 0.04) 2011 Modelled IHME
0.03 (0.02 - 0.04) 2010 Modelled IHME
0.03 (0.02 - 0.04) 2009 Modelled IHME
0.03 (0.02 - 0.04) 2008 Modelled IHME
0.03 (0.02 - 0.04) 2007 Modelled IHME
0.03 (0.02 - 0.04) 2006 Modelled IHME
0.03 (0.02 - 0.04) 2005 Modelled IHME
0.03 (0.02 - 0.04) 2004 Modelled IHME
0.03 (0.02 - 0.04) 2003 Modelled IHME
0.03 (0.02 - 0.04) 2002 Modelled IHME
0.03 (0.02 - 0.04) 2001 Modelled IHME
0.03 (0.02 - 0.04) 2000 Modelled IHME
0.09 (0.07 - 0.12) 1999 Modelled IHME
0.24 (0.17 - 0.31) 1998 Modelled IHME
0.4 (0.29 - 0.52) 1997 Modelled IHME
0.54 (0.40 - 0.70) 1996 Modelled IHME
0.6 (0.44 - 0.78) 1995 Modelled IHME
0.6 (0.44 - 0.78) 1994 Modelled IHME
0.6 (0.44 - 0.78) 1993 Modelled IHME
0.6 (0.44 - 0.77) 1992 Modelled IHME
0.6 (0.43 - 0.78) 1991 Modelled IHME
0.59 (0.41 - 0.79) 1990 Modelled IHME
0.56 (0.37 - 0.79) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
19 (13 - 26) 2019 Modelled IHME
19 (13 - 27) 2018 Modelled IHME
19 (13 - 27) 2017 Modelled IHME
19 (14 - 27) 2016 Modelled IHME
19 (14 - 27) 2015 Modelled IHME
20 (14 - 27) 2014 Modelled IHME
20 (14 - 27) 2013 Modelled IHME
20 (14 - 27) 2012 Modelled IHME
20 (14 - 27) 2011 Modelled IHME
20 (14 - 27) 2010 Modelled IHME
20 (14 - 28) 2009 Modelled IHME
21 (15 - 29) 2008 Modelled IHME
21 (15 - 29) 2007 Modelled IHME
22 (16 - 30) 2006 Modelled IHME
22 (16 - 30) 2005 Modelled IHME
22 (16 - 31) 2004 Modelled IHME
22 (16 - 31) 2003 Modelled IHME
22 (16 - 30) 2002 Modelled IHME
22 (16 - 30) 2001 Modelled IHME
22 (16 - 30) 2000 Modelled IHME
22 (16 - 30) 1999 Modelled IHME
22 (16 - 30) 1998 Modelled IHME
22 (16 - 31) 1997 Modelled IHME
22 (16 - 31) 1996 Modelled IHME
22 (16 - 30) 1995 Modelled IHME
23 (16 - 31) 1994 Modelled IHME
23 (16 - 30) 1993 Modelled IHME
23 (16 - 31) 1992 Modelled IHME
23 (16 - 31) 1991 Modelled IHME
23 (16 - 31) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
96 2018 Survey/reported WHO/UNICEF
96 2017 Survey/reported WHO/UNICEF
96 2016 Survey/reported WHO/UNICEF
96 2015 Survey/reported WHO/UNICEF
97 2014 Survey/reported WHO/UNICEF
98 2013 Survey/reported WHO/UNICEF
99 2012 Survey/reported WHO/UNICEF
99 2011 Survey/reported WHO/UNICEF
99 2010 Survey/reported WHO/UNICEF
99 2009 Survey/reported WHO/UNICEF
99 2008 Survey/reported WHO/UNICEF
99 2007 Survey/reported WHO/UNICEF
99 2006 Survey/reported WHO/UNICEF
99 2005 Survey/reported WHO/UNICEF
99 2004 Survey/reported WHO/UNICEF
99 2003 Survey/reported WHO/UNICEF
99 2002 Survey/reported WHO/UNICEF
99 2001 Survey/reported WHO/UNICEF
98 2000 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
17 (10 - 24) 2015 Survey/reported EMCDDA, 2017; EMCDDA, 2016.
Technical notes
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
None

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.08 (0.87 - 1.32) 2019 Modelled IHME
1.08 (0.88 - 1.31) 2018 Modelled IHME
1.08 (0.88 - 1.31) 2017 Modelled IHME
1.08 (0.88 - 1.31) 2016 Modelled IHME
1.08 (0.88 - 1.32) 2015 Modelled IHME
1.08 (0.89 - 1.33) 2014 Modelled IHME
1.09 (0.89 - 1.33) 2013 Modelled IHME
1.09 (0.89 - 1.34) 2012 Modelled IHME
1.1 (0.89 - 1.34) 2011 Modelled IHME
1.1 (0.89 - 1.35) 2010 Modelled IHME
1.08 (0.89 - 1.32) 2009 Modelled IHME
1.05 (0.87 - 1.27) 2008 Modelled IHME
1.01 (0.84 - 1.20) 2007 Modelled IHME
0.98 (0.82 - 1.15) 2006 Modelled IHME
0.96 (0.81 - 1.13) 2005 Modelled IHME
0.96 (0.81 - 1.13) 2004 Modelled IHME
0.96 (0.81 - 1.13) 2003 Modelled IHME
0.96 (0.81 - 1.13) 2002 Modelled IHME
0.96 (0.81 - 1.13) 2001 Modelled IHME
0.96 (0.81 - 1.13) 2000 Modelled IHME
0.96 (0.81 - 1.13) 1999 Modelled IHME
0.96 (0.81 - 1.14) 1998 Modelled IHME
0.97 (0.81 - 1.15) 1997 Modelled IHME
0.98 (0.82 - 1.16) 1996 Modelled IHME
0.99 (0.83 - 1.17) 1995 Modelled IHME
1.01 (0.84 - 1.19) 1994 Modelled IHME
1.03 (0.86 - 1.22) 1993 Modelled IHME
1.06 (0.88 - 1.26) 1992 Modelled IHME
1.1 (0.89 - 1.33) 1991 Modelled IHME
1.14 (0.91 - 1.39) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
2 (1.40 - 2.70) 2002 Survey/reported Schreter, 2007
1.4 (0.90 - 2) 2014 Modelled Gower et al, 2014
Showing out of
Show more
People who inject drugs (PWID)
Download
Value (%) Year Type Source
56.1 (35.60 - 76.70) 2014 Modelled Degenhardt L et al, 2017

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
25 (17 - 33) 2019 Modelled IHME
25 (17 - 33) 2018 Modelled IHME
25 (18 - 33) 2017 Modelled IHME
25 (18 - 33) 2016 Modelled IHME
25 (18 - 32) 2015 Modelled IHME
25 (17 - 33) 2014 Modelled IHME
25 (18 - 32) 2013 Modelled IHME
25 (18 - 33) 2012 Modelled IHME
25 (18 - 33) 2011 Modelled IHME
25 (17 - 33) 2010 Modelled IHME
25 (18 - 33) 2009 Modelled IHME
25 (17 - 32) 2008 Modelled IHME
25 (17 - 33) 2007 Modelled IHME
25 (17 - 32) 2006 Modelled IHME
25 (17 - 32) 2005 Modelled IHME
24 (17 - 32) 2004 Modelled IHME
24 (17 - 32) 2003 Modelled IHME
24 (17 - 32) 2002 Modelled IHME
24 (17 - 32) 2001 Modelled IHME
24 (17 - 32) 2000 Modelled IHME
24 (16 - 31) 1999 Modelled IHME
23 (16 - 31) 1998 Modelled IHME
23 (16 - 31) 1997 Modelled IHME
23 (16 - 31) 1996 Modelled IHME
23 (17 - 31) 1995 Modelled IHME
23 (16 - 31) 1994 Modelled IHME
23 (16 - 31) 1993 Modelled IHME
23 (16 - 30) 1992 Modelled IHME
23 (16 - 31) 1991 Modelled IHME
23 (16 - 31) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (10 - 24) 2015 Survey/reported EMCDDA, 2017; EMCDDA, 2016.
Technical notes
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
None

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
0.81 (%)
2019
(0.69 - 0.93(%))
IHME
HCV (RNA/cAg+)
1.08 (%)
2019
(0.87 - 1.32(%))
IHME

Survey/surveillance

HBV (HBsAg+)
1.1 (%)
2003
(0.7 - 1.6(%))
Nardone A et al, 2009
HCV (anti-HCV)
2 (%)
2002
(1.4 - 2.7(%))
Schreter, 2007

Hepatitis related deaths (national)

Modelled

HBV
359
2019
(248 - 507)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
399
2019
(274 - 564)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.04 (%)
2019, latest modelled
(0.03 - 0.05(%))
IHME

Prevalence PWID

HCV
56.10 (%)
2014, latest modelled
(35.60 - 76.70(%))
Degenhardt L et al, 2017

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
17
2015
(10 - 24)
EMCDDA, 2017; EMCDDA, 2016.
Eligible for HBV generic medicines
Eligible for HCV generic medicines